Wound Management Divestiture Allows IsoTis To Pursue Bone Matrix Growth
This article was originally published in The Gray Sheet
Executive SummaryIsoTis will focus exclusively on orthobiologics such as the recently launched Accell TBM bone graft putty after selling its wound management line to DFB Pharmaceuticals
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.